Company
Delta-Fly Pharma, Inc.
Headquarters: Tokushima, Japan
Employees: 11
Market Cap
¥6.51 Billion
JPY as of July 1, 2025
US$45.4 Million
Delta-Fly Pharma, Inc. Categories
Japan Healthcare BiotechnologyJapan Healthcare Japan Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323 to treat lung cancer; DFP-17729, DFP-11207, and DFP-14927 for the treatment of solid tumors; and DFP-10825 for peritoneal metastasis. The company was founded in 2010 and is headquartered in Tokushima, Japan.
Stocks & Indices
Delta-Fly Pharma, Inc. has the following listings and related stock indices.
Stock: JPX: 4598 wb_incandescent